Dariusz M. Kowalski

机构：Inserm, Université de Lille, Centre Hospitalier Universitaire de Lille, National Institute of Oncology, Centre de Recherche en Cancérologie de Lyon, The Maria Sklodowska-Curie National Research Institute of Oncology, Onco Lille, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers · ORCID：0000-0002-9452-3229

发表论文 332 篇 · 总被引 28755 次 · h-index 44

代表论文

• Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study (2025 · Journal of Clinical Oncology · 被引 50)
• A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC (2025 · Journal of Thoracic Oncology · 被引 49)
• Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial (2025 · Journal of Thoracic Oncology · 被引 6)
• Anticoagulant therapy in patients with cancer and thrombocytopenia (2025 · Journal of Thrombosis and Thrombolysis · 被引 6)
• Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743 (2026 · Journal of Clinical Oncology · 被引 5)
• Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study (2025 · Journal of Thoracic Oncology · 被引 3)